Short answer
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Ironwood’s recent business activities and quarter ended September 30, 2026.
IRONWOOD PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Ironwood’s recent business activities and quarter ended September 30, 2026
- Exhibit 99.1 contains the company’s operating update and financial results details
Item EX-99.1 · Exhibit EX-99.1
- Raised 2026 LINZESS U.S. sales guidance to $1.20-$1.25B, signaling sustained demand and improved net pricing
- Raised 2026 revenue guidance to $485-$510M and adjusted EBITDA above $350M, strengthening earnings expectations
- Q3 revenue $133.0M, GAAP net income $59.8M, and record adjusted EBITDA $97.9M
- LINZESS U.S. sales $324.9M, up 3.2%, with prescription demand up 4.9% and collaboration profit up 9.8%
- Cash $86.4M and revolving debt $325.0M after $60.0M repayment, while STARS-2 remains on track for planned 2029 filing seeking apraglutide approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IRONWOOD PHARMACEUTICALS INC 8-K filings
Get the next IRWD 8-K as it lands
Follow IRWD for push alerts, or ask the research agent what this filing means.